Sign in
Active, not recruitingPhase 4

Low Level Laser Therapy With Injectable Platelet Rich Fibrin in Management of Oral Lichen Planus

Key facts

Who runs it
Ain Shams University
Where
Egypt1 site in 1 countryChoose a country to see its sites
Trial code
Status
Active, not recruiting
Phase
Phase 4
People taking part
39 people enrolled
Started
15 Mar 2026
Expected to end
20 May 2027
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Injectable Platelet Rich Fibrin
  • Low Level Laser Therapy
  • Triamcinolone acetonide (injection)
Record updated
29 September 2026

Who can take part

Age
40 years to 60 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 5 criteriaShow less

Who can take part

  • Clinically and histologically proven painful Bullous/ erosive or atrophic forms of OLP

Who cannot take part

  • 1- History of drug induced lichenoid lesions. 2. Presence of systemic conditions as; serious active or recurrent infections, malignancy, diabetes mellitus, hypertension, or significant heart, liver, or renal diseases
  • Smoking. 4. Pregnancy or breast-feeding. 5. Loss of pliability or flexibility in the tissues involved by the oral lesions of lichen planus
  • Histological signs of epithelial dysplasia or lichenoid lesions within the biopsied sites
  • Refusing to participate in the study. 8. Vulnerable groups (handicapped)

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The Injectable PRF (i-PRF) is a variant of PRF, which is a liquid blood derivative rich in leukocytes and acts as a growth factor release, with its potential anti-inflammatory role, it may alleviate the symptoms of OLP.

Read full original descriptionShow less

Low Level Laser Therapy (LLLT) emits short wavelength red or infrared light between (500-1100 nm) with a low water absorption. This light can reach a depth of 3 mm to 15 mm in both soft and hard tissues, the biostimulatory effect of laser irradiation results in physiological, metabolic, and functional changes in living microorganisms. The investigators compared the clinical effectiveness of LLLT combined with (i-PRF) to the application of (i-PRF) alone and to that of topical corticosteroid regimen in symptomatic OLP and investigated therapeutic mechanism by examining treatment effect on expression of Tumor necrosis factor alpha (TNF-alpha) and Vascular endothelial growth factor (VEGF) in salivary samples from OLP patients.

The 3 groups in the trial

  • Injectable Platelet Rich Fibrin (i-PRF)Treatment being tested

    1 ml of (i-PRF) obtained after centrifuging 10 ml of peripheral venous blood from OLP patient, will be injected once weekly for 1 month.

    Treatment: Injectable Platelet Rich Fibrin

  • Low Level Laser therapy (LLLT) / (i -PRF)Treatment being tested

    1 ml of (i- PRF) once weekly for 1 month followed by (LLLT) at 940 nm for 180 seconds twice weekly, 8 sessions for 1 month.

    Treatment: Injectable Platelet Rich Fibrin and Low Level Laser Therapy

  • Topical corticosteroidExisting treatment, for comparison

    Injectional triamcinolone acetonide (TA) (40 mg/ml; Epico) once weekly for 1 month

    Treatment: Triamcinolone acetonide (injection)

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Low Level Laser Therapy Combined With Injectable Platelet Rich Fibrin Versus Injectable Platelet Rich Fibrin in Management of Symptomatic Oral Lichen Planus : A Randomized Controlled Clinical Study With Biochemical Analysis
Record updated
29 September 2026